CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Ventyx Biosciences announces $100m IPO

By Daniel Tyson

20:00, 30 September 2021

Ventyx Biosciences does medical research
Medical research at Ventyx Bioscience - Photo: Shutterstock

Ventyx Biosciences, a medical research company which focusses on therapies for inflammatory diseases and autoimmune disorders, filed for a $100m initial public offering Wednesday.

The company’s Securities and Exchange Commission’s filing did not list the number of shares or a price range the company hopes to sell when its shares are sold on the Nasdaq under the ticker "VTYX."

Also on Thursday, the Encinitas, California-based lab said it closed on a $51m Series B convertible preferred stock finding round.

Jefferies, Evercore ISI, Piper Sandler, and LifeSci Capital are acting as joint book-runners.

Read more: No time to buy: Here are 43 James Bond investments

Related topics

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading